Dexamethasone use in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: this "cort" is not out of order!
作者信息
Van Praet Charles, Fonteyne Valérie, Lumen Nicolaas
机构信息
Department of Urology, Ghent University Hospital, Ghent 9000, Belgium.
Department of Radiation Oncology, Ghent University Hospital, Ghent 9000, Belgium.
出版信息
Asian J Androl. 2022 Mar-Apr;24(2):225. doi: 10.4103/aja202155.
Abstract
摘要
相似文献
1
Dexamethasone use in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: this "cort" is not out of order!地塞米松在接受醋酸阿比特龙治疗的转移性去势抵抗性前列腺癌患者中的应用：这种“皮质”并无异常！
Asian J Androl. 2022 Mar-Apr;24(2):225. doi: 10.4103/aja202155.
2
Re: Abiraterone and Olaparib for Metastatic Castration-resistant Prostate Cancer.关于：阿比特龙和奥拉帕尼用于转移性去势抵抗性前列腺癌
Eur Urol. 2024 Apr;85(4):396. doi: 10.1016/j.eururo.2023.11.014. Epub 2023 Nov 27.
3
Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.化疗初治转移性去势抵抗性前列腺癌患者接受恩扎卢胺或醋酸阿比特龙联合泼尼松治疗的经济学结局。
Adv Ther. 2020 May;37(5):2083-2097. doi: 10.1007/s12325-020-01260-x. Epub 2020 Feb 28.
4
A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.一项关于日本转移性去势抵抗性前列腺癌患者中醋酸阿比特龙序贯多西他赛治疗的多中心回顾性分析。
Jpn J Clin Oncol. 2015 Aug;45(8):774-9. doi: 10.1093/jjco/hyv070. Epub 2015 May 15.
5
Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study.醋酸阿比特龙联合泼尼松治疗一线去势治疗失败的转移性去势抵抗性前列腺癌患者的疗效和安全性：一项单臂、4 期研究。
Jpn J Clin Oncol. 2021 Apr 1;51(4):544-551. doi: 10.1093/jjco/hyaa225.
6
Study of cases of abiraterone discontinuation due to toxicity in pre-chemotherapy after 1 year's experience.在经历一年之后，对化疗前因毒性而停用阿比特龙的病例进行研究。
J Oncol Pharm Pract. 2017 Dec;23(8):615-619. doi: 10.1177/1078155216674354. Epub 2016 Oct 17.
7
Predictors of efficacy of corticosteroid switching from abiraterone plus prednisone to dexamethasone in patients with metastatic castration-resistant prostate cancer.预测转移性去势抵抗性前列腺癌患者从阿比特龙联合泼尼松转换为地塞米松治疗疗效的因素。
Asian J Androl. 2022 Mar-Apr;24(2):154-160. doi: 10.4103/aja202143.
8
A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study).醋酸阿比特龙在未经化疗的日本转移性去势抵抗性前列腺癌男性患者中的2期试验（JPN - 201研究）
Jpn J Clin Oncol. 2014 Dec;44(12):1216-26. doi: 10.1093/jjco/hyu149. Epub 2014 Oct 15.
9
Clinical Experience of Steroid Switch from Prednisone to Dexamethasone in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate.醋酸阿比特龙治疗转移性去势抵抗性前列腺癌患者中泼尼松龙转换地塞米松的临床经验。
Urol Int. 2021;105(5-6):380-385. doi: 10.1159/000509882. Epub 2020 Aug 13.
10
Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.醋酸阿比特龙联合泼尼松治疗转移性去势抵抗性前列腺癌患者后的雄激素信号靶向治疗的临床结局：COU-AA-302 的事后分析。
Eur Urol. 2017 Jul;72(1):10-13. doi: 10.1016/j.eururo.2017.03.007. Epub 2017 Mar 15.
引用本文的文献
1
Effect of Dexamethasone on Abiraterone Pharmacokinetics in Mice: Determined by LC/MS Analysis.地塞米松对小鼠阿比特龙药代动力学的影响：通过液相色谱/质谱分析测定
Medicines (Basel). 2023 Mar 6;10(3):21. doi: 10.3390/medicines10030021.
本文引用的文献
1
Predictors of efficacy of corticosteroid switching from abiraterone plus prednisone to dexamethasone in patients with metastatic castration-resistant prostate cancer.预测转移性去势抵抗性前列腺癌患者从阿比特龙联合泼尼松转换为地塞米松治疗疗效的因素。
Asian J Androl. 2022 Mar-Apr;24(2):154-160. doi: 10.4103/aja202143.
2
Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer: A Randomized, Open-label Phase 2 Study.醋酸阿比特龙联合糖皮质激素方案治疗转移性去势抵抗性前列腺癌的安全性评估：一项随机、开放标签的2期研究。
JAMA Oncol. 2019 Aug 1;5(8):1159-1167. doi: 10.1001/jamaoncol.2019.1011.
3
A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer.地塞米松与泼尼松龙治疗去势抵抗性前列腺癌的随机 2 期临床试验。
Eur Urol. 2015 Apr;67(4):673-9. doi: 10.1016/j.eururo.2014.10.004. Epub 2014 Oct 16.
4
Glucocorticoid receptor signaling and prostate cancer.糖皮质激素受体信号与前列腺癌。
Cancer Lett. 2011 Mar 1;302(1):1-10. doi: 10.1016/j.canlet.2010.10.020.
5
Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma.前列腺特异性抗原水平及低剂量地塞米松对激素难治性转移性前列腺癌的临床反应
Cancer. 1995 Jul 1;76(1):96-100. doi: 10.1002/1097-0142(19950701)76:1<96::aid-cncr2820760114>3.0.co;2-e.
Zotero 插件